Gentian Diagnostics ASA (OSL:GENT)

Market Cap	891.41M
Revenue (ttm)	163.38M
Net Income (ttm)	42.19M
Shares Out	15.42M
EPS (ttm)	2.65
PE Ratio	21.85
Forward PE	35.86
Dividend	0.40 (0.69%)
Ex-Dividend Date	May 7, 2025

Volume	59
Average Volume	2,516
Open	57.80
Previous Close	57.80
Day's Range	57.80 - 57.80
52-Week Range	37.00 - 65.80
Beta	0.36
RSI	51.08
Earnings Date	Oct 23, 2025

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT